Apotea AB (publ) med organisationsnummer 556864-7324
Sweden · SE0023313762 · reports in SEK · Europe
Four figures
From the annual report for the year to Dec 31, 2025. Each line says what it is based on.
- Revenue growth
- Revenue +10% in the year to Dec 31, 2025, on the year before.
- Return on equity
- It earned 27% on its shareholders' equity in the year to Dec 31, 2025.
- Equity and assets
- Equity is 43% of its assets, and operations brought in cash in the year.
- Price and earnings
- Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.
The year
Year to Dec 31, 2025, consolidated, in SEK.
revenue
operating margin
net profit
Year by year
As filed; an earlier year can differ from its own report when the company restated it.
| Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|
| Revenue | SEK 5.5B | SEK 6.5B | SEK 7.2B |
| Operating profit | SEK 114M | SEK 266M | SEK 298M |
| Net profit to shareholders | SEK 87M | SEK 215M | SEK 229M |
| Earnings per share | SEK 0.85 | SEK 2.09 | SEK 2.20 |
| Cash from operations | SEK 216M | SEK 206M | SEK 333M |
| Capital spending | SEK 120M | SEK 163M | SEK 213M |
| Cash | SEK 19M | SEK 27M | SEK 31M |
| Total assets | SEK 1.3B | SEK 1.6B | SEK 2.0B |
| Equity | SEK 425M | SEK 636M | SEK 860M |
What they do
In the company's own words, from the annual report.
Moder-bolaget och dess dotterbolags verksamhet (sammantaget ”koncernen” eller "bolaget") omfattar försäljning av apoteksvaror inklusive läkemedel, hälso- och hygienprodukter samt försäljning av vitaminer, hälsokost och övriga varor. Verksamheten omfattar även tjänster som utgörs av leasing, uthyrning av personal till närstående bolag och marknadsbidrag.
Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the ratios from the filed figures.